The effect of ω-3 polyunsaturated fatty acids on the liver lipidome, proteome and bile acid profile: parenteral versus enteral administration

Bechyňská, Kamila; Ďásková, Nikola; Vrzáčková, Nikola; Harant, Karel; Heczková, Marie; Podzimkova, Katerina; Brátová, Miriam; Daňková, Helena; Berková, Zuzana; Kosek, Vít; Zelenka, Jaroslav; Hajšlová, Jana; Sedláček, Radislav; Suttnar, Jiřı́; Hlaváčková, Alžběta; Bartoňová, Lenka; Cahová, Monika

doi:10.1038/s41598-019-54225-8

Cited by 14 publications

(16 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Physiological BAs spectrum. All these findings may contribute to the explanation of ω-3 PUFA protective effects in the context of PN [37].…”

Section: Mechanisms Of Lipid Toxicity Observed In Laboratory Animals mentioning

confidence: 69%

“…Bechynska et al in an effort to understand the underlying mechanism of PNALD took a different approach and determined serum and liver lipidome, liver proteome, liver bile acid profile as well as markers of inflammation oxidative stress in rats admin-istered either ω-6 PUFA based lipid emulsion (Intralipid) or ω-6/ω-3 PUFA blend (Intralipid/Omegaven) via the enteral or parenteral route in rats [37]. They showed that PN administered omega-3 polyunsaturated fatty acids (ω-3 PUFA), compared with parenterally administered Intralipid, and was associated with 1.…”

Section: Mechanisms Of Lipid Toxicity Observed In Laboratory Animals mentioning

confidence: 99%

See 1 more Smart Citation

Intravenous Lipid Emulsions in the Prevention and Treatment of Liver Disease in Intestinal Failure

Rochling

2021

Nutrients

View full text Add to dashboard Cite

The development of intestinal failure-associated liver disease (IFALD) in pediatric and adult patients on parenteral nutrition is usually multifactorial in nature due to nutritional and non-nutritional causes. The role of lipid therapy as a contributing cause is well-established with the pathophysiological pathways now better understood. The review focuses on risk factors for IFALD development, biological effects of lipids, lipid emulsions and the mechanisms of lipid toxicity observed in laboratory animals followed by a synopsis of clinical studies in pediatric and adult patients. The introduction of fish oil-based lipid emulsions that provide partial or complete lipid replacement therapy has resulted in resolution of IFALD that had been associated with soybean oil-based therapy. Based on case reports and cohort studies in pediatric and adult patients who were at risk or developed overt liver disease, we now have more evidence that an early switch to partial or complete fish oil–based lipid therapy should be implemented in order to successfully halt and reverse IFALD.

show abstract

“…Physiological BAs spectrum. All these findings may contribute to the explanation of ω-3 PUFA protective effects in the context of PN [37].…”

Section: Mechanisms Of Lipid Toxicity Observed In Laboratory Animals mentioning

confidence: 69%

Section: Mechanisms Of Lipid Toxicity Observed In Laboratory Animals mentioning

confidence: 99%

Intravenous Lipid Emulsions in the Prevention and Treatment of Liver Disease in Intestinal Failure

Rochling

2021

Nutrients

View full text Add to dashboard Cite

show abstract

“…The total malondialdehyde concentration in the plasma was determined after alkaline hydrolysis with sodium hydroxide using the liquid chromatography-tandem mass spectrometry (LC-MS/MS) method according to Bechynska et al [17].…”

Section: Determination Of Malondialdehyde Concentration In Plasmamentioning

confidence: 99%

Fibrin Clot Formation under Oxidative Stress Conditions

et al. 2021

Self Cite

View full text Add to dashboard Cite

During coagulation, the soluble fibrinogen is converted into insoluble fibrin. Fibrinogen is a multifunctional plasma protein, which is essential for hemostasis. Various oxidative posttranslational modifications influence fibrinogen structure as well as interactions between various partners in the coagulation process. The aim was to examine the effects of oxidative stress conditions on fibrin clot formation in arterial atherothrombotic disorders. We studied the changes in in vitro fibrin network formation in three groups of patients—with acute coronary syndrome (ACS), with significant carotid artery stenosis (SCAS), and with acute ischemic stroke (AIS), as well as a control group. The level of oxidative stress marker malondialdehyde measured by LC-MS/MS was higher in SCAS and AIS patients compared with controls. Turbidic methods revealed a higher final optical density and a prolonged lysis time in the clots of these patients. Electron microscopy was used to visualize changes in the in vitro-formed fibrin network. Fibers from patients with AIS were significantly thicker in comparison with control and ACS fibers. The number of fibrin fibers in patients with AIS was significantly lower in comparison with ACS and control groups. Thus, oxidative stress-mediated changes in fibrin clot formation, structure and dissolution may affect the effectiveness of thrombolytic therapy.

show abstract

“…EPA and DHA are proving to be increasingly versatile in their benefits with newer research which broadens the spectrum of their actions through modes of administration other than oral. In a study conducted by Bechynska et al (2019) a dietary formulation of n‐3 fatty acids versus n‐6 fatty acids was administered enterally and parenterally, to compare the effects on liver lipidome and BA profile, as an effort to understand the protective role of n‐3 fatty acids in parenteral nutrition. Although, it was concluded that although the inclusion of n‐3 fatty acids in the nutrition mixtures facilitated prevention and reversal of liver disease associated with parenteral nutrition, the mechanisms for these benefits remain unknown.…”

Section: Influence Of N‐3 Fatty Acids On Ba Signaling Pathwaysmentioning

confidence: 99%

Role of n‐3 Fatty Acids on Bile Acid Metabolism and Transport in Dyslipidemia: A Review

Acharya

Uppin

Zarei

et al. 2020

Lipids

View full text Add to dashboard Cite

Dietary n‐3 fatty acids, especially of marine origin, eicosapentaenoic acid (20:5n‐3) and docosahexaenoic acid (22:6n‐3), have always been lauded for their profound effects on regulating the risk factors for major metabolic disorders. Yet, their consumption rate is poor compared to n‐6 fatty acids [linoleic acid (18:2n‐6)], which are predominantly consumed. Hence, the skewed n‐6 to n‐3 fatty acid ratio may have a bearing on the risk factors of various diseases, including dyslipidemia. Dyslipidemia and other lifestyle diseases associated with it, such as diabetes, obesity, hypertension, are a growing concern in both developed and developing countries. A common strategy for addressing dyslipidemia involves bile acid (BA) sequestration, to interrupt the enterohepatic circulation of BA, resulting in the modulation of lipid absorption in the intestine, thereby normalizing the levels of circulating lipids. The BA homeostasis is under the tight control of hepatic and enteric BA transporters. Many investigations have reported the effects of dietary constituents, including certain fatty acids on the reabsorption and transport of BA. However, a critical review of the effects of n‐3 fatty acids on BA metabolism and transport is not available. The present review attempts to explore certain unmapped facets of the n‐3 fatty acids on BA metabolism and transport in dyslipidemia, and their interplay with biological processes involving lipid rafts and gut microbiome.

show abstract

The effect of ω-3 polyunsaturated fatty acids on the liver lipidome, proteome and bile acid profile: parenteral versus enteral administration

Cited by 14 publications

References 58 publications

Intravenous Lipid Emulsions in the Prevention and Treatment of Liver Disease in Intestinal Failure

Intravenous Lipid Emulsions in the Prevention and Treatment of Liver Disease in Intestinal Failure

Fibrin Clot Formation under Oxidative Stress Conditions

Role of n‐3 Fatty Acids on Bile Acid Metabolism and Transport in Dyslipidemia: A Review

Contact Info

Product

Resources

About